Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: C09DX04

Entresto(sacubitril;valsartan)

Heart Failure

Marketing Authorisation Holder: Novartis Europharm Limited

EMA Authorisation: 19/11/2015

INN: sacubitril;valsartan

Indication

Paediatric heart failure Entresto is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction. Adult heart failure Entresto is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Entresto — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.